AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

5-Hydroxytryptamine Receptor 6, Pipeline Review, H2 2019 - Alla Chem LLC, HEC Pharm Co Ltd & Reviva Pharmaceuticals Inc - ResearchAndMarkets.com

January 21, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 21, 2020--

The “5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

According to the recently published report ‘5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2019’; 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - The 5-HT6 receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin. Blockade of 5-HT6 receptors showed to increase glutamatergic and cholinergic neurotransmission in brain, whereas activation enhances GABAergic signaling in a widespread manner. Antagonism of 5-HT6 receptors facilitates dopamine and norepinephrine release in the frontal cortex while stimulation has the opposite effect. 5-HT6 receptor plays an important role in Alzheimer’s disease and other forms of dementia and obesity.

The report ‘5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2019’ outlays comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders and Respiratory which include indications Psychiatric Disorders, Alzheimer’s Disease, Cognitive Disorders, Schizophrenia, Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Autism, Bipolar Disorder (Manic Depression), Dementia, Depression, Generalized Anxiety Disorder (GAD), Idiopathic Pulmonary Fibrosis, Major Depressive Disorder, Neurology, Obesity, Parkinson’s Disease, Psychosis, Pulmonary Arterial Hypertension and Schizoaffective Disorder.

Scope

Reasons to buy

Key Topics Covered:

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tyadmq

View source version on businesswire.com:https://www.businesswire.com/news/home/20200121005497/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/21/2020 05:02 AM/DISC: 01/21/2020 05:02 AM

http://www.businesswire.com/news/home/20200121005497/en